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Chemotherapy-induced neuropathy (CIPN) has a relevant impact on the quality of life of cancer patients. There are no curative
conventional treatments, so further options have to be investigated. We conducted a systematic review in English and Chinese
language databases to illuminate the role of medical herbs. 26 relevant studies on 5 single herbs, one extract, one receptor-
agonist, and 8 combinations of herbs were identified focusing on the single herbs Acorus calamus rhizoma, Cannabis sativa fructus,
Chamomilla matricaria, Ginkgo biloba, Salvia officinalis, Sweet bee venom, Fritillaria cirrhosae bulbus, and the herbal combinations
Bu Yang HuanWu, modified Bu Yang HuanWu plus Liuwei Di Huang, modified Chai Hu Long GuMu LiWan, Geranii herba plus
Aconiti lateralis praeparata radix , NiuChe SenQiWan (Goshajinkigan), Gui Zhi Jia Shu FuTang (Keishikajutsubuto),HuangQiWu
Wu Tang (Ogikeishigomotsuto), and Shao Yao Gan Cao Tang (Shakuyakukanzoto). The knowledge of mechanism of action is still
limited, the quality of clinical trials needs further improvement, and studies have not yielded enough evidence to establish a standard
practice, but a lot of promising substances have been identified. While CIPN has multiple mechanisms of neuronal degeneration, a
combination of herbs or substances might deal with multiple targets for the aim of neuroprotection or neuroregeneration in CIPN.
1. Introduction
Several chemotherapeutic drugs are known to be neurotoxic
and can lead to chemotherapy-induced peripheral neuropa-
thy (CIPN). It is one of the main dose-limiting toxicities
in oncologic treatments and a potential reason to terminate
or suspend chemotherapy, in some cases leading to disease
progression [1]. CIPN involves damage to the peripheral
nervous system and can produce severe neuropathic pain
[2, 3], sensory deficits, or gait impairment [4] and can severely
decrease the patient’s quality of life [5]. Sensory symptoms
usually develop before motor symptoms, because motor
neurons are more myelinated [6, 7]. Distal parts of the axons
are the first affected, so sensory symptoms typically start
symmetrically and bilaterally from the tips of the toes and fin-
gers and progress proximally in a “stocking-glove” distribu-
tion [8]. The incidence of CIPN can reach levels of up to
92% [9].Themajor groups of drugs that induce CIPN include
the antitubulins (paclitaxel, docetaxel, ixabepilone, and
vincristine), platinum analogs (cisplatin, carboplatin, and
oxaliplatin), and the proteasome inhibitors bortezomib and
thalidomide [1]. Patients with a preexisting other cause of
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peripheral neuropathy develop more severe and persistent
CIPN [10–12].
The development of CIPN is usually dependent on the
cumulative dose and symptoms may progressively aggravate
[10]. After sustaining therapy symptoms are usually rever-
sible, but in some cases they may be irreversible [10, 13] and
sometimes even progress after stoppingmedication, especial-
ly after treatment with vinca alkaloids (e.g., vincristine), plat-
inum analogues (e.g., cisplatin and oxaliplatin), and taxanes
(e.g., paclitaxel) [14, 15]. Mostly the sensory nerve cell bodies
of the dorsal root ganglia are affected, or the afferent and
efferent distal peripheral axons are damaged [16].
Some differences concerning the mechanisms of CIPN
are described for different therapeutic drugs.
In platinum compounds the dorsal root ganglia are the
main parts of the nervous systems that are injured [17] and
apoptosis is induced via structural alterations of DNA and
of cell-cycle kinetics [18], triggered by oxidative stress and
mitochondrial dysfunction but possibly downregulated by a
reduction of enzymes like p53 [19–22].
The taxanes paxlitaxel and docetaxel are antitubulins
and mainly damage the soma of the sensory neurons and
the nerve axons. This is induced by an interference with
the axonal transport, which is caused by enhancement of
microtubule polymerization [23]. Microglial activation in
the spinal cord and high concentration in the dorsal root
ganglia tissue induce CIPN [24]. Like platinum compounds,
taxanes can damage dorsal root ganglia. This is induced
by macrophage activation in the dorsal root ganglia but
occurs also in the peripheral nerve [24]. Paclitaxel induces a
massive polar reconfiguration of axonal microtubules and an
impairment of organelle transport [25].
Vinca alkaloids (e.g., vincristine) prevent tubulin poly-
merization from soluble dimers into microtubules [26]. By
affecting the tubulin dimers loss of axonal microtubules and
alterations in their length, arrangement and orientation are
produced [27, 28]. This alters the neuronal cytoskeleton,
leading to abnormalities in axonal transport and axonal
degeneration [28, 29]. Decreasing affinity for tubulin of the
vinca alkaloids explains the different neurotoxicity profiles
and the severity of CIPN [30].
Epothilones (e.g., ixabepilone) are like the taxanes anti-
tubulins, so there might be similar mechanisms of peripheral
neurotoxicity. They damage the ganglion soma cells and
peripheral axons through disruption of microtubules of the
mitotic spindle and interfere with the axonal transport in
the neurons [31] and can also induce polymerization of
tubulin dimers in microtubules. Additionally they stabilize
preformed microtubules against conditions favouring de-
polymerization [32, 33].
Bortezomib might induce pathological changes in
Schwann cells and myelin, axonal degeneration, and dorsal
root ganglia neuron changes [34, 35], as well as chromatolysis
of dorsal root ganglial neurons. It causes cytoplasmic accu-
mulation of eosinophilic material [36] and interferes with
the transcription, nuclear processing and transport, as well
as with the cytoplasmic translation of messenger RNAs in
dorsal root ganglions [37]. Mitochondrial and endoplasmic
reticulum-mediated calcium dysregulation plays an impor-
tant part [38, 39]. The activation of the mitochondria-based
apoptotic pathway or inhibition of the transcription of the
nerve growth factor by interference with the nuclear factor-
𝜅B pathway can lead to disarrangement of the neurotrophin
network [39, 40]. Bortezomib can induce changes in all
major primary afferent fibres [41].
The structure of thalidomide is characterized by a 3-
substituted glutarimide ring and a ph-thalimide ring, which
are sensitive to enzymatic or nonenzymatic hydrolysis [42],
but despite several studies it has not been possible to identify
the responsible enzymes for the production of neurotoxic
metabolites, so its mechanism of peripheral neurotoxicity is
still elusive [43].
Multiple drugs have been tested,mainly in animal studies,
for their putative neuroprotective activity in CIPN. A few
components which can protect different tissues from toxic
agents were clinically tested, showing conflicting results. No
conclusive reports confirming their effectiveness have been
provided [44, 45] and a reduction of anticancer activity was
suspected [46]. Several neurotrophins were tested but there
was no evidence of neuroprotection [47–50]. Erythropoietin,
a multifunctional trophic factor, showed promising results in
preclinical studies [51, 52] but has relevant safety problems
[53].
Antioxidants have been tested as neuroprotectants [54–
59], but no conclusive evidence of neuroprotection has yet
been found.
Neuropathic pain is conventionally treated by antiepilep-
tic and tricyclic antidepressant drugs, but these drugs are
ineffective for treatment of decreased sensation and cannot
induce neuroprotection or neuroregeneration. Other com-
pounds with different mechanisms (e.g., acetyl-L-carnitine,
glutamate carboxypeptidase II inhibitors, calpain inhibitors,
a solution of calcium and magnesium) have now been
investigated in preclinical stages with unknown value for
clinical routine [59–63].
Thus specific and effective curative treatments for CIPN
are lacking, especially those meant for enhancing neurore-
generation or neuroprotection [64–67], and the evaluation of
further treatment options is of great importance. While the
effectiveness of herbal treatment is not well known yet, this
review was done to illuminate the actual and potential future
role of herbal treatment in CIPN.
2. Methods
To review the existing clinical and experimental studies of
herbal treatment in CIPN, a systematic literature search
was performed from the databases from inception up until
January 2013 using MEDLINE, Google Scholar, Cochrane
Database, CINHAL (Cumulative Index toNursing andAllied
Health Literature), CNKI (ChinaNational Knowledge Infras-
tructure), and Wanfang Med Online and ISI Proceedings for
conference abstracts.The keywords searched were as follows:
(Chinese herbs or herbs or plants or Chinese medicine
as MeSH term) AND (neuropathy or chemotherapy). The
CINHAL, CNKI, and Wanfang Med Online Databases did
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not allow logical searches with AND, so we used simple
combinations of the search words. Historical searches of
reference lists of relevant articles were also undertaken.
To be included in our review a study had to focus on the
topic CIPN and neuropathy in human and animal models
irrespective of design. Papers with at least an English abstract
were included. Study selection was performed by two review-
ers (SSch and KB) with disagreement resolved by discussion
and adjudication.
Listed articles concerning diseases other than CIPN and
herbal treatment were excluded, while animal products used
in the tradition of herbal medicine were included.
3. Results
A total of 3474 (1477 in English and 1997 in Chinese databas-
es) articles were retrieved by way of electronic searches and
examination of reference lists of clinical and review articles.
After screening titles and/or abstracts, 3376 articles were
excluded because either the focus was on an intervention
other than CIPN and herbal treatment or they were dupli-
cated studies or not relevant. From a total of 98 articles which
were retrieved for detailed evaluation, 15 were included in the
review, focusing on 5 single herbs, one extract, one receptor
agonist, and 8 combinations of herbs. For a summary of the
experimental and clinical studies see Table 1.
3.1. Single Herbs or Single Herbal Compounds
3.1.1. Acorus calamus rhizoma . This herb (family: Araceae)
is traditionally used in the treatment and management of
pain and severe inflammatory in Ayurveda. It is commonly
used to relieve the muscle, joint, vascular and nerve injury
associated with severe inflammatory and neuropathic pain
[68]. In a rat model a hydroalcoholic extract of Acorus
calamus rhizoma has been shown to exert beneficial effect on
neuropathic pain induced by tibial and sural nerve transec-
tion [69]. In a further study Acorus calamus rhizoma extract
attenuated sciatic nerve chronic constriction injury and
induced ameliorated behavioral (hyperalgesia and allody-
nia), biochemical (superoxide anion, myeloperoxidase, and
total calcium), and histopathological (axonal degeneration)
changes [68]. Another study investigated the protective effect
of Acorus calamus rhizoma extract in vincristine-induced
painful neuropathy. Hydroalcoholic extracts of Acorus cala-
mus rhizoma attenuated vincristine-induced behavioral and
biochemical changes to an extent comparable to pregabalin
(positive control) and attenuated vincristine-induced painful
neuropathy, which probably may be attributed to its multiple
effects including antioxidative, anti-inflammatory, and cal-
cium inhibitory activity [70].
3.1.2. Cannabis sativa. Two structurally distinct cannabi-
noid CB2 agonists—the aminoalkylindole (R,S)-AM1241
((R,S)-(2-iodo-5-nitrophenyl)-[1-((1-methyl-piperidin-2–
yl)methyl)-1H-indol-3-yl]-methanone) and the cannabilac-
tone AM1714 (1,9-dihydroxy-3-(1󸀠,1󸀠-dimethylheptyl)-6H-
benzo[c]chromene-6-one))—had been tested for their
dose related suppression of established paclitaxel-evoked
mechanical allodynia in a rat model. (R)-AM1241, but not (S)-
AM1241, suppressed paclitaxel evoked mechanical allodynia,
and AM1714 induced a modest antinociceptive effect. So
the authors suggested that cannabinoid CB2 receptors
may be important therapeutic targets for the treatment of
chemotherapy-evoked neuropathy [71]. Cannabis sativa or
Cannabis extracts have not been clinically explicitly tested
for CIPN but for other clinical conditions like neuropathic
pain in HIV [72]. Multiple clinical trials examined the effect
on neuropathic pain and found positive effects on central
and peripheral neuropathic pain with different forms of
application [73–82].
3.1.3. Matricaria chamomilla. This is a commonly used
herb in western as well as in eastern phytopharmacological
tradition. Flavonoids from Matricaria chamomilla seem to
have an antispasmodic effect and main components such as
𝛼-bisabolol or chamazulene have anti-inflammatory effects
[83]. En-In-Dicycloether has both antispasmodic and anti-
inflammatory effects together [84]. In a mouse model it was
shown that Matricaria chamomilla extract-treated mice had
a significant reduction of cisplatin-induced peripheral pain
[85]. Matricaria chamomilla hydroalcoholic extract was able
to decrease cisplatin-induced pain and inflammation better
than morphine [85].
3.1.4. Ginkgo biloba. The popular herb from the maidenhair
tree that has shown some promising effects as an neuro-
protectant. The most unique components of the extracts are
the terpene trilactones, that is, ginkgolides and bilobalide
[109]. In vitro and ex vivo studies indicate that bilobalide has
multiple mechanisms of action that may be associated with
neuroprotection, including its preservation of mitochondrial
ATP synthesis, its inhibition of apoptotic damage induced by
staurosporine or by serum-free medium, its suppression of
hypoxia-induced membrane deterioration in the brain, and
its action in increasing the expression of the mitochondrial
DNA-encoded COX III subunit of cytochrome C oxidase
and the ND1 subunit of NADH dehydrogenase [110]. Because
multiple modes of action may apply to bilobalide, it could
be useful in developing therapy for neurodegeneration [109–
111]. Oztu¨rk et al. investigatedGinkgo biloba alcoholic extract
in cisplatin-induced peripheral neuropathy in mice [86].
Development of neuropathy was evaluated with changes in
sensory nerve conduction velocity (NCV) and Ginkgo biloba
extract prevented reduction in NCV. In another study a
Ginkgo biloba extract prevented some functional and mor-
phological deteriorations induced by cisplatin, antagonizing
the decrease in the number of migrating cells and in the
length of outgrowing axons [86]. Marshall et al. investi-
gated retrospectively 17 patients with colorectal cancer who
received oxaliplatin along with Ginkgo biloba extract, but
no specification of the extraction method was provided in
the published abstract. The researchers found that 11 of the
17 patients developed a grade 1 peripheral neuropathy (PN)
after the first cycle of oxaliplatin. Five of six patients who
received Ginkgo biloba after the second cycle of oxaliplatin
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reported decreased intensity and duration of sensory PN. No
Ginkgo biloba related side effects have been observed. The
data suggested thatGinkgo biloba extract appears to attenuate
the intensity and duration of acute dysesthesias caused by
oxaliplatin and may yield synergistic antitumor activity [87].
3.1.5. Salvia officinalis. Salvia species and their isolated con-
stituents possess significant antioxidant activity in enzyme-
dependent and enzyme-independent systems [112–115]. The
flavonoid apigenin, for example, has been shown to protect
neurons against A𝛽-induced toxicity [116]. In addition to
antioxidant activity, many salvia species and their isolated
constituents showed anti-inflammatory properties [117, 118].
Salvia officinalis extract can have anti-inflammatory and also
antinociceptive effects on chemical behavioral models of
nociception in mice that involve an opioid mechanism [119].
An animal study showed the effects of the Salvia officinalis
hydroalcoholic extract on vincristine-induced PN in mice in
comparison with morphine with a decrease of pain response,
suggesting that Salvia officinalis extract could be useful in the
treatment of vincristine-induced peripheral neuropathic pain
[88].
3.1.6. Sweet bee venom. The venom of honey bees with its
active peptide Melittin has been tested for injection into
the acupuncture point Zusanli (ST 36) for its effect on
CIPN in animal models. It showed to alleviate thermal
hyperalgesia and mechanical allodynia. The results indicated
an association with the activation of the LC noradrenergic
system and with a reduction in spinal pNR1 [120, 121].
In a first case series this was tested in 5 patients in a
1-week course of treatment, which showed no side effects
and gave evidence of clinical improvement [89]. Another
prospective case series of this procedure analyzed the clinical
observations made on 11 CIPN patients treated with Sweet
bee venom. A total of 11 eligible consecutive CIPN patients
were treated for 3 weeks and observed for another 3 weeks. A
significant intraindividual improvement was found for pain
and neuropathy scales [90].
3.1.7. Verticinone from Fritillaria bulbus. Verticinone, an
isosteroidal alkaloid isolated from Fritillaria bulbus, was
evaluated inmice for its analgesic activities inmurinemodels
of inflammatory and neuropathic pain. It was shown that oral
administration of hydroalcoholic extracted verticinone could
significantly inhibit acetic acid-induced writhing response
in a dose-dependent manner superior to acetylsalicyl acid.
In the rat model of paclitaxel induced neuropathic pain, in
contrast to the declined analgesic effect of morphine after
repeated administration with the same dose, a relatively
constant analgesic effect of verticinone was observed, so ver-
ticinone is expected to become a potentially novel sedative-
analgesic agent without producing tolerance [91].
3.2. Herbal Combinations
3.2.1. Bu Yang Huan Wu (Chin.) = Tonify the Yang to
Restore Five-Tenths Decoction (Engl.). Bu Yang Huan Wu is
a classical combination of Chinese herbs, first mentioned
in Wang Qing-Ren’s Yi Lin Gai Cuo (Correcting the Errors
in the Field of Medicine) published in 1830 [122]. This
recipe contains Astragalus membranaceus radix, Angelica
sinensis radix, Prunus persicae semen, Paeoniae rubra radix,
Ligustici chuanxiong rhizoma, Lumbricus terrestris, Spatholobi
caulis, Curcuma radix, Chaenomeles lagenaria fructus, and
Achyranthes bidentatae radix.
The decoction has been used in a randomized Chinese
study of 84 patients (treatment group 𝑛 = 44, control group
𝑛 = 40) after the treatment of oxaliplatin and showed reduced
development of CIPN in the treatment group tested by stand-
ardized clinical tests [92].
3.2.2. Modified Bu Yang Huan Wu (Chin.) = Tonify the
Yang to Restore Five-Tenths Decoction (Engl.) plus Liuwei Di
Huang (Chin.) = Rokumijiogan (Jap.) = Pilula Rehmannia
Sex Saporum (Lat.) = Six Ingredients Pill with Rehmannia
(Engl.). In another randomized Chinese study a modified
combination of two standard recipes Bu Yang Huan Wu
and Liuwei Di Huang was tested as a decoction. Liuwei Di
Huang was first described in the Yozheng Zhijue [123]. The
mixture of both recipes contains Astragalus membranaceus
radix, Ligustrum lucidum fructus, Paeoniae rubra radix, Lum-
bricus terrestris, Prunus persicae semen, Rehmanniae viride
radix, Corni officinalis fructus, Dioscorea opposita radix; and
Alismatis rhizoma, Poria alba, Spatholobi caulis, Scolopendra,
Mori fructus, Glycyrrhizae radix, Dipsaci fructus, Lycii fruc-
tus, Coicis semen, Atractylodis rhizoma, Phellodendri cortex,
Scorpio, Mori ramulus, and Cyathula officinalis.
The remaining dregs of decoction were additionally used
for washing the lower extremities. The treatment was used
on 32 patients with existing CIPN following different chemo-
therapies and compared with 32 patients who were treated
orally with vitamin B1 2500 ug plus by intramuscular injec-
tion with vitamin B1 100mg. Herbal treatment was found
to be significantly more effective to vitamin treatment (𝑃 <
0.05) [93].
3.2.3. Modified Chai Hu Long Gu Mu Li Wan (Chin.) =
Modified Saikokaryukotsuboreito (Jap.) = Modified Formula
bupleurum cum ostrea et Fossilia ossis (Lat.) = Modified
Bupleurum, Dragon Bone, and Oyster Shell Formula (Engl.).
Chai Hu Long Gu Mu Li Wan is a traditional recipe derived
from the Shang Han Lun [124]. A modification of this
recipe was used in a Chinese randomized trial in which
48 patients with ovarian cancer were examined parallel to
chemotherapy with placitaxel. They were divided into a
treatment group with paclitaxel alone and a treatment group
with paclitaxel plus a combination of oral Chinese herbal
decoction treatment and external washing of the feet with
Chinese herbs.
The oral combination of herbs consists of Pseudostellaria
heterophylla, Pinelliae rhizoma, Glycyrrhizae radix, Scutel-
laria baicalensis radix, Bupleuri radix, Fossilia ossis mastodi,
Ostreae concha, Rubia cordifolia radix, Scutellariae barbatae
herba, and Fritillariae thunbergii bulbi. The external washing
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was done with Astragali membranaceus radix, Angelica sinen-
sis radix, Paeoniae rubra radix, Lumbricus terrestris, Ligustici
chuanxiong rhizoma, Prunus persicae semen, and Carthami
flos.
The incidence of CIPN was almost half as high in the
patients treated additionally with Chinese herbs as evaluated
by clinical testing (𝑃 < 0.05) [94].
3.2.4. Geranii herba plus Aconiti radix. External application
of a combination of Geranii herba and Aconiti radix extract
has been shown to be effective in a rat model of oxali-
platin evoked neuropathy. Mechanical allodynia and thermal
hyperalgesia were alleviated. NGF was increased, substance
P decreased in the group treated with Geranii herba and
Aconiti radix extract additionally to oxaliplatin compared to
oxaliplatin alone [95].
In the following randomized clinical study 58 patients
with CIPN from oxaliplatin, taxol, or capecitabine were
assigned prospectively in a controlled randomized trial: 30
patients were assigned to the study group and 28 were used as
a control. The clinical study revealed that symptoms of pain,
paraesthesia, and swelling were relieved after one week of
therapy and it was concluded that Geranii herba plus Aconiti
radix granule can relieve neuropathy and improve the quality
of life. Unfortunately the authors did not provide data in the
published abstract, which species of Geranii herba or Aconiti
radix they used [95].
3.2.5. Goshajinkigan (Jap.) = Niu Che Sen Qi Wan (Chin.) =
Pilula renales plantaginis et achyranthis (Lat.) = Life Preserv-
ing Kidney Qi Pill (Engl.). This formula derives from the
Jisheng Fang, written by Yan Yonghe, a little known but highly
regarded physician of the Song Dynasty, published in 1253
[125]. In Japanese Kampomedicine it is called Goshajinkigan
(GJG) and is frequently used as a standardized granule. It con-
tains 10 different herbs (Rehmannia viride radix, Achyranthis
bidentatae radix, Corni fructus, Dioscorea opposita rhizoma,
Plantaginis semen, Alismatis rhizoma, Moutan cortex, Cin-
namomi cortex, Aconiti lateralis praeparata tuber, and Poria
alba) [126]. GJG has antioxidant properties [127, 128].
GJG was tested for its effect on CIPN in animal studies.
In a rat model of oxaliplatin-induced neuropathy repeated
administration of GJG prevented the oxaliplatin-induced
cold hyperalgesia but not mechanical allodynia and axonal
degeneration of the rat sciatic nerve. A single administration
of GJG reduced both cold hyperalgesia and mechanical
allodynia after the development of neuropathy. GJG did not
affect the antitumour effect of oxaliplatin on the tumour cells
or mice implanted with tumour cells [98].
GJG was also tested in a rat model for paclitaxel-induced
peripheral neuropathy, but as with oxaliplatin no regenera-
tionwas found in histological examination [96]. Nevertheless
further rat animal studies showed a positive effect of GJG on
cold allodynia [97].
GJG has been widely used to treat symptoms like numb-
ness, vibration sensation, cold sensation, and limb pain
associated with diabetic neuropathy [129].
It has been shown to prevent oxaliplatin-induced periph-
eral neuropathy in a FOLFOX-regimen (FOL: Folinic acid
(leucovorin), F: Fluorouracil (5-FU), OX: Oxaliplatin (Elox-
atin)) in clinical studies [99, 100]. In a noncontrolled study
14 patients received GJG every day after the first oxaliplatin
infusion. GJG seemed to prevent acute oxaliplatin-induced
neurotoxicity [99]. In a retrospective analysis of 45 patients,
22 received GJG during their FOLFOX regimen against
nonresectable or recurrent colorectal cancer, while 23 did
not get this additional therapy. The incidence of grade 3
PN in the GJG group was significantly lower than in the
control group (𝑃 < 0.01, log-rank test). The incidence
of grade 3 PN after 10 courses of chemotherapy was 0%
in the GJG group and 12% in the control group, and after
20 courses was 33% in the GJG group and 75% in the
control group [100]. A further retrospective analysis was
performed in 90 patients who were given a FOLFOX regimen
for metastatic colorectal cancer. Two treatment groups were
compared: FOLFXOX plus GJG and FOLFOX plus GJG
plus Ca2+/Mg+, and two control groups: FOLFOX without
additional therapy and FOLFOX plus Ca2+/Mg+. When a
cumulative dose of oxaliplatin exceeded 500mg/m2, the
incidence of PN was 91% in the FOLFOX without additional
therapy group, 100% in the FOLFOX group with additional
Ca2+/Mg+ therapy, and 79% in the FOLFOX plus GJG plus
Ca2+/Mg+ therapy group and 50% in the GJG plus FOLFOX
group.The cumulative oxaliplatin dose when 50% of patients
developed neurotoxicity was 765mg/m2 in the GJG plus
FOLFOX and 340mg/m2 in the FOLFOX plus GJG plus
Ca2+/Mg+ group, respectively, and 255mg/m2 in both control
groups.The authors concluded that concomitant administra-
tion of GJG reduced the neurotoxicity of oxaliplatin without
having a negative influence on the response rate [101], so for
further validation of these data a concept for a prospective,
controlled, double blinded randomized study was developed
[130].
GJG was also tested for paclitaxel-induced neuropathy
in breast and gynecological cancer. A retrospective study on
82 patients found that GJG was possibly effective for the
treatment and the prevention of peripheral neuropathy and
seemed to be more effective when administered from the
beginning of chemotherapy using paclitaxel [102].
In a prospective study in paclitaxel/carboplatin treated
patients with ovarian or endometrial cancer, patients were
randomly divided into two groups. 14 patients received
vitamin B12 and 15 patients vitamin B12 plus GJG. The
observation period was 6 weeks following treatment initi-
ation. A NCI-CTCAE (National Cancer Institute-Common
Toxicity criteria) grade 3 of neurotoxicity developed in 2
patients (14.3%) after 6 weeks in the vitamin B12, whereas
no neurotoxicity was observed in the vitamin B12/GJG
group. The change in the frequency of abnormal current
perception threshold (CPT) ratio was significantly lower in
the VB12/GJG group in comparison to VitB12 alone (𝑃 <
0.05), which suggests that GJG inhibits the progression of PN
[103].
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3.2.6. Keishikajutsubuto (Jap.) = Gui Zhi Jia Shu Fu Tang
(Chin.) = Decoctum ramulorum cassiae cum atractylodis
macrocephae et aconiti (Lat.) =CinnamonTwigDecoction plus
Atractylodes and Aconite (Engl.). This formula has its basis
from the Shang Han Lun andwas further developed as a Japa-
nese experimental formula during the Edo period (1603 to
1868). It contains Cinamomi cortex, Aconiti lateralis praepa-
rata tuber, Zingiberis rhizoma, Jujubae fructus, Glycyrrhizae
radix, and Atracylodis macrocephalae rhizoma.
This herbal combinationwith an increased dose ofAconiti
lateralis praeparata tuber was used as a granule for 11 patients
with metastatic colorectal cancer receiving FOLFOX in a
noncontrolled study. Reduction of neuropathy was observed
in 5 cases after chemotherapy (45.5%) [104].
The same herbal granule was also used in a study on
postherpetic neuralgia and was found to be effective. In three
of 15 patients in this noncontrolled trial continuation of the
treatment with Keishikajutsubuto was not possible due to
hot flashes or gastric discomfort. The remaining 12 patients
showed a VAS improvement rate of 76.5 ± 27.7% (mean ±
standard deviation) [131].
3.2.7. Ogikeishigomotsuto (Jap.) = Huang Qi Wu Wu Tang
(Chin.) = (Decotum quinque medicamentorum cum astragalo
(Lat.) = Astragalus and Cinnamon Five Herb Combination
(Engl.). This classical combination derives from Jin Gui Yao
Lue (Essential Prescriptions from the Golden Chamber)
[132]. In Kampo medicine it is called Ogikeishigomotsuto,
containingAstragalimembranaceus radix, Cinnamomi cortex,
Paeonia alba radix, Jujubae fructus, and Zingiberis rhizoma. It
has been used in individual cases for neuropathic pain due to
ANCA-associated vasculitis [133].
In single case report the granule showed a positive effect
on neuropathic pain and it allowed the continuation of the
suspended chemotherapy with oxaliplatin [105].
3.2.8. Shakuyakukanzoto (Jap.) = Shao Yao Gan Cao Tang
(Chin.), Formula glycyrrhizae et paeonia (Lat.), Peony and
Licorice Decoction (Engl.). This classical formula derives
from the ShangHan Lun [124]. In Kampomedicine it is called
Shakuyakukanzoto and it is a herbal granule of Paeonia alba
radix and Glycyrrhizae radix. It is used to relieve menstrual
pain and muscle spasm as well as muscle pain due to the
chemotherapeutic agents paclitaxel and carboplatin [134–
136] and has also been tested for CIPN. A retrospective case
analysis of 23 patients showed a positive effect on neuropathic
pain in CIPN after paclitaxel for ovarian carcinoma [107].
This was supported by animal studies in a mouse model
of paclitaxel-induced pain. Shakuyakukanzoto significantly
relieved the allodynia and hyperalgesia induced by paclitaxel
[106]. Shakuyakukanzoto has also been tested for prevent-
ing neurotoxic side effects of FOLFOX and the effect was
retrospectively compared to the treatment with GJG (see
Section 3.2.5). 44 patients with metastatic colorectal cancer
received FOLFOX and concurrently received either GJG (𝑛 =
20) or Shakuyakukanzoto (𝑛 = 24).The responsewas 50.0% in
the GJG and 65% in the Shakuyakkanzoto group.The authors
concluded that both recipes are able to reduce the FOLFOX-
induced neurotoxicity [108].
3.3. Herbs Tested or Herbal Ingredients for Neuropathic Pain,
Not Specifically Tested to CIPN. Capsaicin is the active
component of chili peppers, which are plants belonging to
the genus Capsicum. Topical creams with capsaicin are used
to treat peripheral neuropathic pain. Following application
to the skin capsaicin causes enhanced sensitivity, followed
by a period with reduced sensitivity and, after repeated
applications, persistent desensitisation.
Topical capsaicin is used to treat postherpetic neuralgia
and HIV-neuropathy and has been found to be effective in
multiple trials.There are risks of epidermal innervation upon
repeated application over long periods [137].
Aconiti lateralis praeparata radix is a herb used in many
recipes for neuropathy like GJG (see Section 3.2.5) and
Keishikajutsubuto (see Section 3.2.6) and is often used for
several types of persistent pain. In a mouse model anal-
gesic effects caused by inhibition of astrocytic activation
by Aconiti lateralis praeparata radix were mimicked by the
intrathecal injection of fluorocitrate. The study indicated
that the activation of spinal astrocytes was responsible for
the late maintenance phase of neuropathic pain, so Aconiti
lateralis praeparata radix could be a therapeutic strategy
for treating neuropathic pain [138]. In a rat model Aconiti
lateralis praeparata radixwas tested against a placebo for allo-
dynia and thermal hyperalgesia. A dose-dependent effect was
measured. The effects were inhibited by intraperitoneal and
intrathecal nor-binaltorphimine, a selective kappa-opioid
receptor antagonist, but not by intraperitoneal naloxone.The
authors concluded that the effect against neuropathic pain is
induced via spinal kappa-opioid receptor mechanisms [139].
Moutan cortex and Coicis semen have been tested posi-
tively in two different neuropathic pain mice models. In one
model allodynia was induced by intrathecal administration
of prostaglandin F2alpha (PGF2alpha) and in the second
model by selective L5 spinal nerve transection.The extracts of
Moutan cortex and Coicis semen dose dependently alleviated
the PGF2alpha-induced allodynia. The increase in NADPH
diaphorase activity in the spinal cord associated with neuro-
pathic pain was also blocked by these extracts. These results
suggest that Moutan cortex and Coicis semen are substances
effective in the treatment of neuropathic pain [140].
Nigella sativa and one main compound thymoquinone
were beneficial on histopathological changes of sciatic nerves
in streptozotocin (STZ) induced diabetic rats. Evaluation of
the tissues in the diabetic animals showed fewermorphologic
alterations, and myelin breakdown decreased significantly
after treatment with Nigella sativa and thymoquinone. The
ultrastructural features of axons also showed improvement
[141].
Ocimum sanctum was investigated in sciatic nerve tran-
section induced peripheral neuropathy in rats. Axonal degen-
eration was assessed histopathologically. Paw pressure, Von
Frey Hair, tail cold-hyperalgesia, and motor in-coordination
tests were performed to assess the in vivo extent of neuropa-
thy. Biochemical estimations of thiobarbituric acid reactive
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species (TBARS), reduced glutathione (GSH), and total
calcium levels were also performed. Ocimum sanctum atten-
uated axonal degeneration, rise in TBARS, total calcium,
and decrease in GSH levels in a dose-dependent manner.
In vivo reduction of nociceptive threshold and motor in-
coordination was found. The authors concluded that anti-
oxidant and calcium attenuating actions may be responsible
for the amelioration [142].
In an another animal study STZ-induced diabetic rats
received intraperitoneal injection of this extract of Teucrium
polium.The treated rats exhibited a lower nociceptive score as
compared to untreated diabetic rats. The results may suggest
a therapeutic potential of Teucrium polium for the treatment
of hyperalgesia [143].
A hexanic extract from Phyllanthus amarus has been
shown to be effective in a neuropathic model of nociception.
The antiallodynic effects seemed not to be associated with the
impairment of motor coordination or with the development
of tolerance. Apart from its anti-inflammatory actions, which
are probably linked to the presence of lignans, another as yet
unidentified active principle(s) present in the hexanic extract
of Phyllanthus amarus produces pronounced anti-allodynia
[144].
An aqueous extract of Sesbania sesbanwas tested in STZ-
induced diabetic rats.The treated group showed an increased
tail flick latency significantly when comparedwith pregabalin
and reduced superoxide anion and total calcium levels which
gave evidence of neuroprotective effects [145].
4. Discussion
In spite of intense research in the last decades, no conven-
tional pharmacological substance has been established as a
sufficient and safe treatment of CIPN-induced neuroprotec-
tion and regeneration [31, 43–63, 65–67]. Herbal treatment is
commonly used for different kind of therapies where western
medicine does not offer a sufficient efficacy, but the evidence
of the use of herbal treatment is not clear and has to be
elucidated.
One main problem of doing research on herbs and
understanding the mechanisms of their action is the fact
that herbs contain a number of active compounds and by
tradition, especially in Asian herbal therapy, combinations of
multiple herbs are common.
Classical research mainly focusing on a single active
compound has been done often without regard to historical
knowledge of the therapeutic utility of the plant source
[146]. This does not reflect the complexity of traditional
Asian herbal recipes, while there is some evidence that
single components extracted from plants are less potent
than the complete extract [147] and a multitarget approach
might be more effective than a single target approach [148].
Pharmacological mixtures can also have the advantage of
potentiating the action of their multiple bioactive compo-
nents and the option of an individualized therapy [149, 150].
For scientific understanding of the mechanisms of action
there is still a need for basic research on single herbs and
their active compounds, but research should not stop at
this level but continue with research of multicompounds,
their interactions, and increasing or decreasing activity in
combinations.
The positive effect of a single herb on neuroprotection or
regeneration was not found in any clinical study and rarely
found in animal studies. Only the flavonoid apigenin from
Salvia officinalis seems to protect neurons against toxicity
[116] andGinkgo biloba as a single herb shows some evidence
of preventing neuronal degeneration and inducing neural
regeneration in CIPN [109–111].
Mainly in animal studies only a few single herbs have been
tested for treatment of CIPN improving neuropathic pain.
This effect might be induced by Acorus calamus rhizoma due
to its antioxidative, anti-inflammatory, and calcium inhibito-
ry actions [70]. Flavonoids fromMatricaria chamomilla have
an antispasmodic and an anti-inflammatory effect [83, 84].
Salvia officinalis is probably working due to its antioxidant
activity and anti-inflammatory properties [112–115] and is
also involved in an opioid mechanism [119]. Fritillaria bulbus
might be effective due to its isosteroidal alkaloid verticinone
[91].WhileCannabis sativa is effective inmultiple and central
pain syndromes [72–78], the fact that two Cannabis agonists
had been shown to be effective in CIPN in a rat model could
be a hint thatCannabis sativamight be a promising substance
for pain in CIPN in the future.
Only Ginkgo biloba extract has been positively tested
in a small retrospective clinical study in humans [87] and
Sweet bee venom had shown positive results by injection into
acupuncture points in a small clinical case series [89, 90].
Topical capsaicin from chili peppers was found to be effective
in multiple trials to treat pain from postherpetic neuralgia
and HIV-neuropathy but has not been specifically tested
against pain in CIPN [137].
There are a fewmore single herbs tested in animalmodels
for the treatment of neuropathic pain in other conditions
than CIPN.Moutan cortex and Coicis semen have been tested
positively in two different neuropathic pain models. Both
herbs dose dependently alleviated the PGF2alpha-induced
allodynia and blocked NADPH diaphorase activity in the
spinal cord associated with neuropathic pain [140].
Nigella sativa, Ocimum sanctum, Teucrium polium, Phyl-
lanthus amarus, and Sesbania sesban also have been tested in
single studies to ameliorate neuropathic pain [141–145].
Aconiti lateralis praeparata radix in a mouse model of
CIPN had analgesic effects by inhibition of spinal astrocytic
activation [138] and in a rat modelAconiti lateralis praeparata
radix had a dose-dependent effect on allodynia and thermal
hyperalgesia which was induced via spinal kappa-opioid
receptor mechanisms [139], which confirmed similar ani-
mal studies on neuropathic pain in diabetic mice [148].
Active components are alkaloids, for example, aconitine and
mesaconitine and have in addition pain-relieving effects,
cardiotonic and vasodilator actions [151–155].
Aconiti lateralis praeparata radix is often used for several
types of persistent pain while it is rarely used as a single herb
for CIPN. But interestingly Aconiti lateralis praeparata radix
is part of many recipes used for CIPN as GJG, Shakuyakukan-
zoto, Keishikajutsubuto, and Geranii herba plus Aconiti radix
combination (see Sections 3.2.4, 3.2.5, 3.2.6, and 3.2.8).
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Some of the pain-relieving effects of GJG are known to be
induced by aconite [139] and it is considered that the analgesic
effect is exerted by the suppression of pain-transmitting
substances release by 𝜅-opioid receptor stimulationmediated
by dynorphin, an endogenous opioid substance released by
processed aconite [148]. But on the other hand, these effects
were stronger, when using of the full recipe in comparison to
the use of Aconiti lateralis praeparata radix alone [155].
GJG is the best tested herbal recipe for CIPN. But not
all details of its mechanism have been clearly identified
and for some ingredients the effects are unknown. It is
considered that the analgesic effect is exerted through the
improvement of peripheral nocireceptor sensitivity, vasodi-
lation, and peripheral circulation by the promotion of NO
production due to the effects of Alismatis rhizoma and
Dioscorea opposita rhizoma mediated by the bradykinin B2
receptor and the muscarinic acetylcholine receptors [148].
Another substance from GJG, Rehmanniae praeparata radix,
could promote the function of learning and memory of MSG
rats, and its mechanism may be related to the increase of
the expression of hippocampal c-fos and nerve growth factor
(NGF) [156], which can be relevant for regeneration in CIPN
as well, while NGF exhibits potent biological activities such
as preventing neuronal death, promoting neurite outgrowth,
and supporting synapse formation [157]. One further mech-
anism of GJG might be its positive effect on improving the
microcirculation, which might be helpful for the recovery of
the nerves in CIPN [158].
Even though the full recipe was clinically positively
tested in a couple of clinical trials, most of them were
uncontrolled or retrospective analyses [99–102, 130] and the
only prospective trial had a limited number of participants
[103]. So the evidence of a positive effect is still low and needs
further clinical and experimental confirmation.
GJG has also been compared to another herbal recipe,
Shakuyakukanzoto, and both were found to be effective in
the treatment of CIPN, but there was no negative control
group [107]. Shakuyakukanzoto was analyzed in a mouse
model [106] and in a retrospective analysis of 23 cases without
controls [108]. Since Shakuyakukanzoto contains only two
herbs, Paeonia alba radix and Glycyrrhizae radix, the future
evaluation of its role for treating CIPN might be easier
than for other herbal recipes. While neuronal apoptosis
can be triggered by oxidative stress and mitochondrial
dysfunction, substances with an antioxidative potency are
possible candidates for treatment of CIPN [19–22], so the
fact that paeoniflorin as one bioactive component of Paeonia
alba radix has been positively tested as an antioxidant in a
nonneuronal cell model might be relevant [159]. It has also
neuroprotective effects which are closely correlated to acti-
vating the adenosine A1 receptor, ameliorating the function
of the cholinergic nerve, regulating ion channel homeostasis,
retarding oxidative stress, apoptosis of the neurocytes, and
promoting nerve growth [160]. Paeonia alba radix was used
in another recipe (see Section 3.2.7) and in two recipes
Paeonia rubra radix (see Sections 3.2.1 and 3.2.2) has been
used. Paeonia alba radix and Paeonia rubra radix have a
lot of similarities in their components and paeoniflorin is a
bioactive compound of both herbs [161].
While the reason for using herbal recipes derives from
historical knowledge or transferral of historical concepts to
modern diseases, interestingly four of eight herbal recipes
tested for CIPN contain Glycyrrhizae radix. To find the
scientific ratio behind this decision, analyses of its action in
the context of neural cell damage might be fruitful.
Another herb that has been used in four of eight herbal
recipes tested for CIPN is Astragalus membranaceus radix.
This might be rational, while Astragalus membranaceus
radix water extracts caused a marked enhancement of the
NGF-mediated neurite outgrowth and the expression of
growth-associated protein 43 from PC12 cells in vitro [162].
Astragalus membranaceus radix extracts can be a potential
nerve growth-promoting factor, being salutary in aiding the
growth of axons in the peripheral nerve [162]. Astragaloside
IV (AGS-IV), one bioactive compound of Astragalus mem-
branaceus radix, is an aldose-reductase inhibitor and a free-
radical scavenger which suppressed a decrease in myelinated
fibers, promoted an increase in myelinated fiber density and
an increase in segmental demyelination in diabetic rats [163].
It also increased the activity of glutathione peroxidase in
nerves, depressed the activation of aldose reductase in ery-
throcytes, decreased the accumulation of advanced glycation
end products in both nerves and erythrocytes, and elevated
Na+, K+-ATPase activity in both the nerves and erythrocytes
of diabetic rats, so it is considered to be protective against the
progression of peripheral neuropathy [163].
The herbal recipeBuYangHuan and amodified extension
have been used in two clinical controlled randomized trials
[92, 93] (3.2.1 and 3.2.2, see above) and was found to be
effective in both. The formula used is very complex, and
little is known about the mechanism of its compound, but
herbs like Astragalus membranaceus radix, Paeonia rubra
radix, and Dioscorea opposita rhizoma are part of the herbal
combinationwhere possiblemechanisms are described (3.2.1,
3.2.2, 3.2.5, 3.2.7, see above), so at least something is known
about its possible mechanisms of effect.
Another study used a modified classical prescription
named Chai Hu Long Gu Mu Li Wan (see Section 3.2.3)
and found positive results as well [94]. Even though it is a
controlled randomized trial, the treatment protocol is very
complicated, combining oral intake of medical herbs and
external washing with other herbs. So also with this herbal
combination little is known about the mechanism of its
action.
Two other herbal recipes have been reported for suc-
cessful clinical use, Keishikajutsubuto = Gui Zhi Jia Shu Fu
Tang (see Section 3.2.6) and Ogikeishigomotsuto =Huang Qi
Wu Wu Tang (see Section 3.2.7). But these studies are either
uncontrolled or a case report, so the quality of the evidence is
very low.
The trials on the single herbs and herbal combinations
tested so far do not provide a clear recommendation for
clinical use. But research on some single herbs as well as on
combinations like GJG is promising, even though the level of
knowledge is limited to basic research on the mechanisms of
action and evidence from clinical trials. But it is necessary to
continue research on this field, while treatment concepts for
CIPN are lacking.
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The most used herbs of herbal recipes in clinical trials
on CIPN are Aconiti lateralis praeparata radix, Rehmannia
praeparata radix, Paeonia (alba and rubra) radix, Astragalus
membranaceus radix, and Glycyrrhizae radix.
In Chinese medicine experience Astragalus membrana-
ceus radix is supporting theQi, whichmeans inwestern terms
supporting the general energy level of the body, which is
usually reduced in CIPN by activating the vegetative nervous
system. Rehmannia praeparata radix is basically supporting
theYin, which inwestern terms reflects the structural damage
of tissue, in the case of CIPN the peripheral nerves. Paeonia
alba radix and Paeonia rubra radix promote the flow of
the Xue, which in western terminology has its correlate in
enhancing the microcirculation which might be reduced
in CIPN; promotion of the perfusion might enhance the
regeneration.
Aconiti lateralis praeparata radix supports in Chinese
medicine theory the Yang. A typical symptom of Yang defi-
ciency is ice-coldness, which is prominent in the extremities
in some cases of CIPN.Glycyrrhizae radix supports the fluids
and has a balancing effect on the whole recipe.
So in spite of using different terms, Chinese medicine
theory describes physical reactions of the body that can be
explained by western physiology and has found its proof by
experimental studies [138, 139, 148, 151–156, 159–164].
So using these herbs has as rational foundation on the
basis of Chinese medical theory as well as from experimental
studies, but unfortunately still little is known about the
complex physiological mechanisms of herbal combinations,
the interactions of the substances, and the mechanisms of
action ofmany other substances used in herbalmedicine.The
challenge for future research is bringing historical knowledge
and modern scientific analysis together.
Due to this limited knowledge on the mechanisms of the
action of herbs, we additionally collected data on herbs that
are a putative treatment option for CIPN. While oxidative
stress and mitochondrial dysfunction promote CIPN, sub-
stances with an antioxidative potency are possible candidates
for the treatment of CIPN. So in the list below we list
herbal antioxidants tested in neuronal cell or disease models.
Additionally we added herbs for enhancement of nerve
growth as putative treatment options for CIPN. NGF exhibits
potent biological activities such as preventing neuronal death,
promoting neurite outgrowth, and supporting synapse for-
mation [157], which has a relevance for the development of
CIPN [39].
Putative Herbs or Herbal Compounds for the Treatment of
CIPN
(1) Herbal Antioxidants Tested in Neuronal Cell or Dis-
ease Models. Puerarin (from Pueraria lobata radix)
[165, 166], Icariin (from Epimedii herba) [167],
a fraction of polysaccharides (from Lycium bar-
barum) [168], Ginsenoside Rg1 (from Notoginseng
panacis) [169], honokiol and magnolol (from Mag-
nolia officinalis) [170], Ginkgolide A, B (from Ginkgo
biloba) [171], huperzine A (from Huperzia serrata)
[171], Ginseng radix [172], Notoginseng panacis
radix [173], 3,5,4󸀠-tetrahydroxystilbene-2-O-beta-D-
glucoside (from Polygonum multiflorum) [174–176],
celastrol (from Tripterygium wilfordii Hook) [177],
Salvianolic acid B (from Salvia miltiorrhiza) [178,
179], tanshinone IIA (from Salvia miltiorrhizae)
[180], Gastrodia elata rhizoma [181, 182], Astraga-
loside IV (from Astragalus membranaceus radix)
[163], Tetramethylpyrazine (from Ligusticum wal-
lichi) [183, 184], Ziziphus spinosus semen [185],
Baicalein (from Scutellaria baicalensis radix Georgi)
[186], Uncaria rhynchophylla [164], 6,7-dihydroxy-
2-methoxy-1,4-phenanthrenedione, chrysoeriol 4󸀠-
O-beta-D-glucopyranoside, chrysoeriol 7-O-beta-D-
glucopyranoside, and alternanthin (from Dioscorea
opposita radix) [187].
(2) Herbs or Herbal Compounds That Enhance Nerve
Growth. Cistanches herba [157, 188], Huperzine A
(HupA) from Huperzia serrata [189, 190], a lipophilic
fraction of panax ginseng [191]. Astragalus membra-
naceus radix [162], Gentiside C, a compound of Gen-
tiana rigescens radix [191], Rehmanniae praeparata
radix [192], Paeoniflorin of Paeonia alba radix [193].
Research with the aim of proving the benefits of promis-
ing substances or herbal combinations has to describe the
mechanism of action for single herbs and single components,
investigate the interactions of combinations of substances,
and analyse the promoting effects of combinations.
From this viewpoint, research in this field has not very
much progressed, but if research does not provide these data,
herbal combinations will not find acceptance in mainstream
treatments in non-Asian countries in Europe,NorthAmerica,
or Australia.
This challenge could be taken if more international coop-
eration of interested research groups would be organized.
5. Conclusion
Experimental and clinical studies have not yielded enough
evidence to establish a standard practice for the treatment
of CIPN, but from this literature review, a lot of promising
substances,mainlyChinesemedical herbswith possible effect
inCIPNor a putative influence onmechanisms of CIPN, have
been identified in the last years.
The knowledge of themechanisms of action is still limited
and the quality of the clinical trials needs further improve-
ment. In the future not only the mechanisms of action for
single herbs and single components have to be described, but
interactions of combinations of substances as well as interac-
tionswith chemotherapy have to be investigated and analysed
in depth. While CIPN has multiple possible mechanisms of
neuronal degeneration, a combination of components might
be a promising opportunity focusing on multiple targets of
degeneration or activating regeneration.
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